Charged particle translation slide control apparatus and method of use thereof

Information

  • Patent Grant
  • 9907981
  • Patent Number
    9,907,981
  • Date Filed
    Friday, December 16, 2016
    7 years ago
  • Date Issued
    Tuesday, March 6, 2018
    6 years ago
Abstract
The invention comprises a system for patient specific control of charged particles in a charged particle beam path using one or more trays inserted into the charged particle beam path, such as at the exit port of a gantry nozzle in close proximity to a tumor of a patient. Each tray holds an insert, such as a patient specific insert for controlling the energy, focus depth, and/or shape of the charged particle beam. Examples of inserts include a range shifter, a compensator, an aperture, a ridge filter, and a blank. Trays in a tray assembly are optionally retracted into an output nozzle of a charged particle cancer treatment system. Optionally and preferably, each tray communicates a held and positioned insert to a main controller of the charged particle cancer therapy system.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

This invention relates generally to treatment of solid cancers. More particularly, the invention relates to nozzle inserts, of a charged particle cancer therapy system, for controlling charged particle density, energy, distribution, and/or shape.


DISCUSSION OF THE PRIOR ART

Cancer Treatment


Proton therapy works by aiming energetic ionizing particles, such as protons accelerated with a particle accelerator, into a target tumor. These particles damage the DNA of cells, ultimately causing their death. Cancerous cells, because of their high rate of division and their reduced ability to repair damaged DNA, are particularly vulnerable to attack on their DNA.


Patents related to the current invention are summarized here.


Proton Beam Therapy System


F. Cole, et. al. of Loma Linda University Medical Center “Multi-Station Proton Beam Therapy System”, U.S. Pat. No. 4,870,287 (Sep. 26, 1989) describe a proton beam therapy system for selectively generating and transporting proton beams from a single proton source and accelerator to a selected treatment room of a plurality of patient treatment rooms.


Imaging


P. Adamee, et. al. “Charged Particle Beam Apparatus and Method for Operating the Same”, U.S. Pat. No. 7,274,018 (Sep. 25, 2007) and P. Adamee, et. al. “Charged Particle Beam Apparatus and Method for Operating the Same”, U.S. Pat. No. 7,045,781 (May 16, 2006) describe a charged particle beam apparatus configured for serial and/or parallel imaging of an object.


K. Hiramoto, et. al. “Ion Beam Therapy System and its Couch Positioning System”, U.S. Pat. No. 7,193,227 (Mar. 20, 2007) describe an ion beam therapy system having an X-ray imaging system moving in conjunction with a rotating gantry.


C. Maurer, et. al. “Apparatus and Method for Registration of Images to Physical Space Using a Weighted Combination of Points and Surfaces”, U.S. Pat. No. 6,560,354 (May 6, 2003) described a process of X-ray computed tomography registered to physical measurements taken on the patient's body, where different body parts are given different weights. Weights are used in an iterative registration process to determine a rigid body transformation process, where the transformation function is used to assist surgical or stereotactic procedures.


M. Blair, et. al. “Proton Beam Digital Imaging System”, U.S. Pat. No. 5,825,845 (Oct. 20, 1998) describe a proton beam digital imaging system having an X-ray source that is movable into a treatment beam line that can produce an X-ray beam through a region of the body. By comparison of the relative positions of the center of the beam in the patient orientation image and the isocentre in the master prescription image with respect to selected monuments, the amount and direction of movement of the patient to make the best beam center correspond to the target isocentre is determined.


S. Nishihara, et. al. “Therapeutic Apparatus”, U.S. Pat. No. 5,039,867 (Aug. 13, 1991) describe a method and apparatus for positioning a therapeutic beam in which a first distance is determined on the basis of a first image, a second distance is determined on the basis of a second image, and the patient is moved to a therapy beam irradiation position on the basis of the first and second distances.


Problem


There exists in the art of charged particle irradiation therapy a need to control energy, cross-sectional beam shape, and/or focal point, of the charged particle beam, where the controls are individualized to individual patients and/or individual tumor shapes.


SUMMARY OF THE INVENTION

The invention comprises a charged particle beam control system.





DESCRIPTION OF THE FIGURES

A more complete understanding of the present invention is derived by referring to the detailed description and claims when considered in connection with the Figures, wherein like reference numbers refer to similar items throughout the Figures.



FIG. 1 illustrates component connections of a charged particle beam therapy system;



FIG. 2 illustrates a charged particle therapy system;



FIG. 3 provides a method of multi-axis charged particle beam irradiation control;



FIG. 4A and FIG. 4B illustrate a top view of a beam control tray and a side view of the beam control tray, respectively.



FIG. 5 illustrates patient specific tray inserts for insertion into the beam control tray; and



FIG. 6A illustrates insertion of the individualized tray assembly into the beam path and FIG. 6B illustrates retraction of the tray assembly into a nozzle of the charged particle cancer therapy system;





Elements and steps in the figures are illustrated for simplicity and clarity and have not necessarily been rendered according to any particular sequence. For example, steps that are performed concurrently or in different order are illustrated in the figures to help improve understanding of embodiments of the present invention.


DETAILED DESCRIPTION OF THE INVENTION

The invention comprises a charged particle beam control tray in a nozzle of a charged particle cancer therapy apparatus and method of use thereof.


In one embodiment, one or more trays are inserted into the positively charged particle beam path, such as at an exit port of a gantry nozzle in close proximity to the patient. Each tray holds an insert, such as a patient specific insert for controlling the energy, focus depth, and/or shape of the charged particle beam. Examples of inserts include a range shifter, a compensator, an aperture, a ridge filter, and a blank. Optionally and preferably, each tray communicates a held and positioned insert to a main controller of the charged particle cancer therapy system.


In another embodiment, a treatment delivery control system (TDCS) or main controller is used to control multiple aspects of the cancer therapy system, including one or more of: an imaging system, such as a CT or PET; a positioner, such as a couch or patient interface module; an injector or injection system; a radio-frequency quadrupole system; a ring accelerator or synchrotron; an extraction system; an irradiation plan; and a display system. The TDCS is preferably a control system for automated cancer therapy once the patient is positioned. The TDCS integrates output of one or more of the below described cancer therapy system elements with inputs of one or more of the below described cancer therapy system elements. More generally, the TDCS controls or manages input and/or output of imaging, an irradiation plan, and charged particle delivery.


In another embodiment, the charged particle tomography apparatus is used in combination with a charged particle cancer therapy system. For example, tomographic imaging of a cancerous tumor is performed using charged particles generated with an injector, accelerator, and guided with a delivery system. The cancer therapy system uses the same injector, accelerator, and guided delivery system in delivering charged particles to the cancerous tumor. For example, the tomography apparatus and cancer therapy system use a common raster beam method and apparatus for treatment of solid cancers. More particularly, the invention comprises a multi-axis and/or multi-field raster beam charged particle accelerator used in tomography and cancer therapy. Optionally, the system independently controls patient translation position, patient rotation position, two-dimensional beam trajectory, delivered radiation beam energy, delivered radiation beam intensity, beam velocity, timing of charged particle delivery, and/or distribution of radiation striking healthy tissue. The system operates in conjunction with a negative ion beam source, synchrotron, patient positioning, imaging, and/or targeting method and apparatus to deliver an effective and uniform dose of radiation to a tumor while distributing radiation striking healthy tissue.


Charged Particle Beam Therapy


Throughout this document, a charged particle beam therapy system, such as a positively charged ion beam, a cation beam, a proton beam, hydrogen ion beam, a cation beam comprising atoms consisting of two to six protons per atom, or carbon ion beam, is described. Herein, the charged particle beam therapy system is described using a proton beam. However, the aspects taught and described in terms of a proton beam are not intended to be limiting to that of a proton beam and are illustrative of a charged particle beam system. Any of the techniques described herein are equally applicable to any charged particle beam system.


Referring now to FIG. 1, a charged particle beam system 100 is illustrated. The charged particle beam preferably comprises a number of subsystems including any of: a main controller 110; an injection system 120; a synchrotron 130 that typically includes: (1) an accelerator system 132 and (2) an extraction system 134; a scanning/targeting/delivery system 140; a patient interface module 150; a display system 160; and/or an imaging system 170.


An exemplary method of use of the charged particle beam system 100 is provided. The main controller 110 controls one or more of the subsystems to accurately and precisely deliver protons to a tumor of a patient. For example, the main controller 110 obtains an image, such as a portion of a body and/or of a tumor, from the imaging system 170. The main controller 110 also obtains position and/or timing information from the patient interface module 150. The main controller 110 then optionally controls the injection system 120 to inject a proton into a synchrotron 130. The synchrotron typically contains at least an accelerator system 132 and an extraction system 134. The main controller 110 preferably controls the proton beam within the accelerator system, such as by controlling speed, trajectory, and timing of the proton beam. The main controller 110 then controls extraction of a proton beam from the accelerator through the extraction system 134. For example, the controller controls timing, energy, and/or intensity of the extracted beam. The controller 110 also preferably controls targeting of the proton beam through the scanning/targeting/delivery system 140 to the patient interface module 150. One or more components of the patient interface module 150, such as translational and rotational position of the patient, are preferably controlled by the main controller 110. Further, display elements of the display system 160 are preferably controlled via the main controller 110. Displays, such as display screens, are typically provided to one or more operators at one or more control stations, and/or to one or more patients. In one embodiment, the main controller 110 times the delivery of the proton beam from all systems, such that protons are delivered in an optimal therapeutic manner to the tumor of the patient.


Herein, the main controller 110 refers to a single system controlling the charged particle beam system 100, to a single controller controlling a plurality of subsystems controlling the charged particle beam system 100, or to a plurality of individual controllers controlling one or more sub-systems of the charged particle beam system 100.


Referring system now to FIG. 2, an illustrative exemplary embodiment of one version of the charged particle beam 100 is provided. The number, position, and described type of components is illustrative and non-limiting in nature. In the illustrated embodiment, the injection system 120 or ion source or charged particle beam source generates protons. The protons are delivered into a vacuum tube that runs into, though, and out of the synchrotron. The generated protons are delivered along an initial path 262. Focusing magnets 230, such as quadrupole magnets or injection quadrupole magnets, are used to focus the proton beam path. A quadrupole magnet is a focusing magnet. An injector bending magnet 232 bends the proton beam toward the plane of the synchrotron 130. The focused protons having an initial energy are introduced into an injector magnet 240, which is preferably an injection Lamberson magnet. Typically, the initial beam path 262 is along an axis off of, such as above, a circulating plane of the synchrotron 130. The injector bending magnet 232 and injector magnet 240 combine to move the protons into the synchrotron 130. Main bending magnets, dipole magnets, turning magnets, or circulating magnets 250 are used to turn the protons along a circulating beam path 264. A dipole magnet is a bending magnet. The main bending magnets 250 bend the initial beam path 262 into a circulating beam path 264. In this example, the main bending magnets 250 or circulating magnets are represented as four sets of four magnets to maintain the circulating beam path 264 into a stable circulating beam path. However, any number of magnets or sets of magnets are optionally used to move the protons around a single orbit in the circulation process. The protons pass through an accelerator 270. The accelerator accelerates the protons in the circulating beam path 264. As the protons are accelerated, the fields applied by the magnets are increased. Particularly, the speed of the protons achieved by the accelerator 270 are synchronized with magnetic fields of the main bending magnets 250 or circulating magnets to maintain stable circulation of the protons about a central point or region 280 of the synchrotron. At separate points in time the accelerator 270/main bending magnet 250 combination is used to accelerate and/or decelerate the circulating protons while maintaining the protons in the circulating path or orbit. An extraction element of the inflector/deflector system 290 is used in combination with a Lamberson extraction magnet 292 to remove protons from their circulating beam path 264 within the synchrotron 130. One example of a deflector component is a Lamberson magnet. Typically the deflector moves the protons from the circulating plane to an axis off of the circulating plane, such as above the circulating plane. Extracted protons are preferably directed and/or focused using an extraction bending magnet 237 and extraction focusing magnets 235, such as quadrupole magnets along a positively charged particle beam transport path 268, such as a beam path or proton beam path, into the scanning/targeting/delivery system 140. Two components of a scanning system 140 or targeting system typically include a first axis control 142, such as a vertical control, and a second axis control 144, such as a horizontal control. In one embodiment, the first axis control 142 allows for about 100 mm of vertical or y-axis scanning of the proton beam 268 and the second axis control 144 allows for about 700 mm of horizontal or x-axis scanning of the proton beam 268. A nozzle system 146 is used for imaging the proton beam and/or as a vacuum barrier between the low pressure beam path of the synchrotron and the atmosphere. In one embodiment, the nozzle 146 or nozzle system includes patient specific hardware, such as a patient specific tray or slide. Protons are delivered with control to the patient interface module 150 and to a tumor of a patient. All of the above listed elements are optional and may be used in various permutations and combinations. Each of the above listed elements are further described, infra.


Proton Beam Extraction


Referring now to FIG. 3, both: (1) an exemplary proton beam extraction process 300 from the synchrotron 130 and (2) a charged particle beam intensity control system 305 are illustrated. For clarity, FIG. 3 removes elements represented in FIG. 2, such as the turning magnets, which allows for greater clarity of presentation of the proton beam path as a function of time. Generally, protons are extracted from the synchrotron 130 by slowing the protons. As described, supra, the protons were initially accelerated in a circulating path 264, which is maintained with a plurality of main bending magnets 250. The circulating path is referred to herein as an original central beamline 264. The protons repeatedly cycle around a central point in the synchrotron 280. The proton path traverses through a radio frequency (RF) cavity system 310. To initiate extraction, an RF field is applied between a first blade 312 and a second blade 314, in the RF cavity system 310. The first blade 312 and second blade 314 are referred to herein as a first pair of blades.


In the proton extraction process, an RF voltage is applied across the first pair of blades, where the first blade 312 of the first pair of blades is on one side of the circulating proton beam path 264 and the second blade 314 of the first pair of blades is on an opposite side of the circulating proton beam path 264. The applied RF field applies energy to the circulating charged-particle beam. The applied RF field alters the orbiting or circulating beam path of the protons slightly from the original central beamline 264 to an altered circulating beam path 265. Upon a second pass of the protons through the RF cavity system, the RF field further moves the protons off of the original proton beamline 264. For example, if the original beamline is considered as a circular path, then the altered beamline is slightly elliptical. The applied RF field is timed to apply outward or inward movement to a given band of protons circulating in the synchrotron accelerator. Each orbit of the protons is slightly more off axis compared to the original circulating beam path 264. Successive passes of the protons through the RF cavity system are forced further and further from the original central beamline 264 by altering the direction and/or intensity of the RF field with each successive pass of the proton beam through the RF field.


The RF voltage is frequency modulated at a frequency about equal to the period of one proton cycling around the synchrotron for one revolution or at a frequency than is an integral multiplier of the period of one proton cycling about the synchrotron. The applied RF frequency modulated voltage induces a betatron oscillation. For example, the oscillation is a sine wave motion of the protons. The process of timing the RF field to a given proton beam within the RF cavity system is repeated thousands of times with each successive pass of the protons being moved approximately one micrometer further off of the original central beamline 264. For clarity, the approximately 1000 changing beam paths with each successive path of a given band of protons through the RF field are illustrated as the altered beam path 265.


With a sufficient sine wave betatron amplitude, the altered circulating beam path 265 touches and/or traverses a material 330, such as a foil or a sheet of foil. The foil is preferably a lightweight material, such as beryllium, a lithium hydride, a carbon sheet, or a material having low nuclear charge components. Herein, a material of low nuclear charge is a material composed of atoms consisting essentially of atoms having six or fewer protons. The foil is preferably about 10 to 150 microns thick, is more preferably about 30 to 100 microns thick, and is still more preferably about 40 to 60 microns thick. In one example, the foil is beryllium with a thickness of about 50 microns. When the protons traverse through the foil, energy of the protons is lost and the speed of the protons is reduced. Typically, a current is also generated, described infra. Protons moving at a slower speed travel in the synchrotron with a reduced radius of curvature 266 compared to either the original central beamline 264 or the altered circulating path 265. The reduced radius of curvature 266 path is also referred to herein as a path having a smaller diameter of trajectory or a path having protons with reduced energy. The reduced radius of curvature 266 is typically about two millimeters less than a radius of curvature of the last pass of the protons along the altered proton beam path 265.


The thickness of the material 330 is optionally adjusted to create a change in the radius of curvature, such as about ½, 1, 2, 3, or 4 mm less than the last pass of the protons 265 or original radius of curvature 264. Protons moving with the smaller radius of curvature travel between a second pair of blades. In one case, the second pair of blades is physically distinct and/or is separated from the first pair of blades. In a second case, one of the first pair of blades is also a member of the second pair of blades. For example, the second pair of blades is the second blade 314 and a third blade 316 in the RF cavity system 310. A high voltage DC signal, such as about 1 to 5 kV, is then applied across the second pair of blades, which directs the protons out of the synchrotron through an extraction magnet 292, such as a Lamberson extraction magnet, into a transport path 268.


Control of acceleration of the charged particle beam path in the synchrotron with the accelerator and/or applied fields of the turning magnets in combination with the above described extraction system allows for control of the intensity of the extracted proton beam, where intensity is a proton flux per unit time or the number of protons extracted as a function of time. For example, when a current is measured beyond a threshold, the RF field modulation in the RF cavity system is terminated or reinitiated to establish a subsequent cycle of proton beam extraction. This process is repeated to yield many cycles of proton beam extraction from the synchrotron accelerator. Intensity control of the charged particle beam is further described, infra.


In another embodiment, instead of moving the charged particles to the material 330, the material 330 is mechanically moved to the circulating charged particles. Particularly, the material 330 is mechanically or electromechanically translated into the path of the circulating charged particles to induce the extraction process, described supra.


In either case, because the extraction system does not depend on any change in magnetic field properties, it allows the synchrotron to continue to operate in acceleration or deceleration mode during the extraction process. Stated differently, the extraction process does not interfere with synchrotron acceleration. In stark contrast, traditional extraction systems introduce a new magnetic field, such as via a hexapole, during the extraction process. More particularly, traditional synchrotrons have a magnet, such as a hexapole magnet, that is off during an acceleration stage. During the extraction phase, the hexapole magnetic field is introduced to the circulating path of the synchrotron. The introduction of the magnetic field necessitates two distinct modes, an acceleration mode and an extraction mode, which are mutually exclusive in time. The herein described system allows for acceleration and/or deceleration of the proton during the extraction step without the use of a newly introduced magnetic field, such as by a hexapole magnet.


Charged Particle Beam Intensity Control


Control of applied field, such as a radio-frequency (RF) field, frequency and magnitude in the RF cavity system 310 allows for intensity control of the extracted proton beam, where intensity is extracted proton flux per unit time or the number of protons extracted as a function of time.


Still referring FIG. 3, the intensity control system 305 is further described. In this example, an intensity control feedback loop is added to the extraction system, described supra. When protons in the proton beam hit the material 330 electrons are given off from the material 330 resulting in a current. The resulting current is converted to a voltage and is used as part of an ion beam intensity monitoring system or as part of an ion beam feedback loop for controlling beam intensity. The voltage is optionally measured and sent to the main controller 110 or to an intensity controller subsystem 340, which is preferably in communication or under the direction of the main controller 110. More particularly, when protons in the charged particle beam path pass through the material 330, some of the protons lose a small fraction of their energy, such as about one-tenth of a percent, which results in a secondary electron being emitted from the material 330. That is, protons in the charged particle beam push some electrons when passing through material 330 giving electrons, in the material 330, enough energy to cause secondary emission. The resulting electron flow results in a current or signal that is proportional to the number of protons going through the target material 330, which allows a direct monitor of the number of protons being extracted. The resulting current is preferably converted to voltage and amplified. The resulting signal is referred to as a measured intensity signal.


The amplified signal or measured intensity signal resulting from the protons passing through the material 330 is optionally used in monitoring the intensity of the extracted protons and is preferably used in controlling the intensity of the extracted protons. For example, the measured intensity signal is compared to a goal signal, which is predetermined in an irradiation of the tumor plan. The difference between the measured intensity signal and the planned for goal signal is calculated. The difference is used as a control to the RF generator. Hence, the measured flow of current resulting from the protons passing through the material 330 is used as a control in the RF generator to increase or decrease the number of protons undergoing betatron oscillation and striking the material 330. Hence, the voltage determined off of the material 330 is used as a measure of the orbital path and is used as a feedback control to control the RF cavity system.


In one example, the intensity controller subsystem 340 preferably additionally receives input from: (1) a detector 350, which provides a reading of the actual intensity of the proton beam and (2) an irradiation plan 360. The irradiation plan provides the desired intensity of the proton beam for each x, y, energy, and/or rotational position of the patient/tumor as a function of time. Thus, the intensity controller 340 receives: (1) the desired intensity from the irradiation plan 350, (2) the actual intensity from the detector 350, and/or (3) a measure of intensity from the material 330 and adjusts the radio-frequency field in the RF cavity system 310 to yield an intensity of the proton beam that matches the desired intensity from the irradiation plan 360.


Charged Particle Beam Control


As described, supra, the photons striking the material 330 is a step in the extraction of the protons from the synchrotron 130. Hence, the measured intensity signal is used to change the number of protons per unit time being extracted, which is referred to as intensity of the proton beam. The intensity of the proton beam is thus under algorithm control. Further, the intensity of the proton beam is controlled separately from the velocity of the protons in the synchrotron 130. Hence, intensity of the protons extracted and the energy of the protons extracted are independently variable.


For example, protons initially move at an equilibrium trajectory in the synchrotron 130. An RF field is used to excite the protons into a betatron oscillation. In one case, the frequency of the protons orbit is about 10 MHz. In one example, in about one millisecond or after about 10,000 orbits, the first protons hit an outer edge of the target material 130. The specific frequency and corresponding energy of the charged particle beam is dependent upon the period of the orbit. Upon hitting the material 130, the protons push electrons through the foil to produce a current. The current is converted to voltage and amplified to yield a measured intensity signal. The measured intensity signal is used as a feedback input to control the applied RF magnitude, RF frequency, or RF field. Preferably, the measured intensity signal is compared to a target signal and a measure of the difference between the measured intensity signal and target signal is used to adjust the applied RF field in the RF cavity system 310 in the extraction system to control the intensity of the protons in the extraction step. Stated again, the signal resulting from the protons striking and/or passing through the material 130 is used as an input in RF field modulation. An increase in the magnitude of the RF modulation results in protons hitting the foil or material 130 sooner. By increasing the RF, more protons are pushed into the foil, which results in an increased intensity, or more protons per unit time, of protons extracted from the synchrotron 130. Notably, the intensity control process is independent of the magnetic fields used to control velocity of the charged particles in the circulating beam path 264. Thus, (1) energy, velocity of the extracted protons and (2) intensity, protons per unit time of the extracted protons are both independently variable and independently controllable.


In another example, a detector 350 external to the synchrotron 130 is used to determine the flux of protons extracted from the synchrotron and a signal from the external detector is used to alter the RF field or RF modulation in the RF cavity system 310. Here the external detector generates an external signal, which is used in a manner similar to the measured intensity signal, described in the preceding paragraphs. Preferably, an algorithm or irradiation plan 360 is used as an input to the intensity controller 340, which controls the RF field modulation by directing the RF signal in the betatron oscillation generation in the RF cavity system 310. The irradiation plan 360 preferably includes the desired intensity of the charged particle beam as a function of time, energy of the charged particle beam as a function of time, for each patient rotation position, and/or for each x-, y-position of the charged particle beam.


In yet another example, when a current from material 130 resulting from protons passing through or hitting material is measured beyond a threshold, the RF field modulation in the RF cavity system is terminated or reinitiated to establish a subsequent cycle of proton beam extraction. This process is repeated to yield many cycles of proton beam extraction from the synchrotron accelerator.


In still yet another embodiment, intensity modulation of the extracted proton beam is controlled by the main controller 110. The main controller 110 optionally and/or additionally controls timing of extraction of the charged particle beam and energy of the extracted proton beam. Optionally and preferably, the main controller 110 directly controls all subsystems of the charged particle cancer therapy system 100 and/or the subsystems thereof. Optionally and preferably, the subsystems of the charged particle cancer therapy systems communicate solely via the main controller 110.


The benefits of the system include a multi-dimensional scanning system. Particularly, the system allows independence in: (1) energy of the protons extracted and (2) intensity of the protons extracted. That is, energy of the protons extracted is controlled by an energy control system and an intensity control system controls the intensity of the extracted protons. The energy control system and intensity control system are optionally independently controlled. Preferably, the main controller 110 controls the energy control system and the main controller 110 simultaneously controls the intensity control system to yield an extracted proton beam with controlled energy and controlled intensity where the controlled energy and controlled intensity are independently variable. Thus the irradiation spot hitting the tumor is under independent control of:

    • time;
    • energy;
    • intensity;
    • x-axis position, where the x-axis represents horizontal movement of the proton beam relative to the patient, and
    • y-axis position, where the y-axis represents vertical movement of the proton beam relative to the patient.


In addition, the patient is optionally independently translated and/or rotated relative to a translational axis of the proton beam at the same time.


Charged Particle Control


Referring now to FIGS. 4A, 4B, 5, 6A, and 6B, a charged particle beam control system is described where one or more patient specific beam control assemblies are removably inserted into the charged particle beam path proximate the nozzle of the charged particle cancer therapy system 100, where the patient specific beam control assemblies adjust the beam energy, diameter, cross-sectional shape, focal point, and/or beam state of the charged particle beam to properly couple energy of the charged particle beam to the individual's specific tumor.


Beam Control Tray


Referring now to FIG. 4A and FIG. 4B, a beam control tray assembly 400 is illustrated in a face on and side view, respectively. The beam control tray assembly 400 optionally comprises any of a tray frame 410, a tray aperture 412, a tray handle 420, a tray connector/communicator 430, and means for holding a patient specific tray insert 510, described infra. Generally, the beam control tray assembly 400 is used to: (1) hold the patient specific tray insert 510 in a rigid location relative to the beam control tray 400, (2) electronically identify the held patient specific tray insert 510 to the main controller 110, and (3) removably insert the patient specific tray insert 510 into an accurate and precise fixed location relative to the charged particle beam, such as the proton beam path 268 at the nozzle of the charged particle cancer therapy system 100.


For clarity of presentation and without loss of generality, the means for holding the patient specific tray insert 510 in the tray frame 410 of the beam control tray assembly 400 is illustrated as a set of recessed set screws 415. However, the means for holding the patient specific tray insert 510 relative to the rest of the beam control tray assembly 400 is optionally any mechanical and/or electromechanical positioning element, such as a latch, clamp, fastener, clip, slide, strap, or the like. Generally, the means for holding the patient specific tray insert 510 in the beam control tray 400 fixes the tray insert and tray frame relative to one another even when rotated along and/or around multiple axes, such as when attached to a charged particle cancer therapy system 100 dynamic gantry nozzle 610 that moves in three-dimensional space relative to a given patient position. As illustrated in FIG. 4A and FIG. 4B, the recessed set screws 415 fix the patient specific tray insert 510 into the aperture 412 of the tray frame 410. The tray frame 410 is illustrated as circumferentially surrounding the patient specific tray insert 510, which aids in structural stability of the beam control tray assembly 400. However, generally the tray frame 410 is of any geometry that forms a stable beam control tray assembly 400.


Still referring to FIG. 4A and now referring to FIG. 5 and FIG. 6A, the optional tray handle 420 is used to manually insert/retract the beam control tray assembly 400 into a receiving element of the gantry nozzle 610. While the beam control tray assembly 400 is optionally inserted into the charged particle beam path 268 at any point after extraction from the synchrotron 130, the beam control tray assembly 400 is preferably inserted into the positively charged particle beam proximate the gantry nozzle 610 as control of the beam shape is preferably done with little space for the beam shape to defocus before striking the tumor. Optionally, insertion and/or retraction of the beam control tray assembly 400 is semi-automated, such as in a manner of a digital-video disk player receiving a digital-video disk.


Patient Specific Tray Insert


Referring again to FIG. 5, a system of assembling trays 500 is described. The beam control tray assembly 400 optionally and preferably has interchangeable patient specific tray inserts 510, such as a range shifter insert 511, a patient specific ridge filter insert 512, an aperture insert 513, a compensator insert 514, or a blank insert 515. As described, supra, any of the range shifter insert 511, the patient specific ridge filter insert 512, the aperture insert 513, the compensator insert 514, or the blank insert 515 after insertion into the tray frame 4610 are inserted as the beam control tray assembly 400 into the positively charged particle beam path 268, such as proximate the gantry nozzle 610.


Still referring to FIG. 5, the patient specific tray inserts 510 are further described. The patient specific tray inserts comprise a combination of any of: (1) a standardized beam control insert and (2) a patient specific beam control insert. For example, the range shifter insert or 511 or compensator insert 514 used to control the depth of penetration of the charged particle beam into the patient is optionally: (a) a standard thickness of a beam slowing material, such as a first thickness of Lucite, (b) one member of a set of members of varying thicknesses and/or densities where each member of the set of members slows the charged particles in the beam path by a known amount, or (c) is a material with a density and thickness designed to slow the charged particles by a customized amount for the individual patient being treated, based on the depth of the individual's tumor in the tissue, the thickness of intervening tissue, and/or the density of intervening bone/tissue. Similarly, the ridge filter insert 512 used to change the focal point or shape of the beam as a function of depth is optionally: (1) selected from a set of ridge filters where different members of the set of ridge filters yield different focal depths or (2) customized for treatment of the individual's tumor based on position of the tumor in the tissue of the individual. Similarly, the aperture insert is: (1) optionally selected from a set of aperture shapes or (2) is a customized individual aperture insert 513 designed for the specific shape of the individual's tumor. The blank insert 515 is an open slot, but serves the purpose of identifying slot occupancy, as described infra.


Slot Occupancy/Identification


Referring again to FIGS. 4A, 4B, and 5, occupancy and identification of the particular patient specific tray insert 510 into the beam control tray assembly 400 is described. Generally, the beam control tray assembly 400 optionally contains means for identifying, to the main controller 110, the specific patient tray insert 510 and its location in the charged particle beam path 268. First, the particular tray insert is optionally labeled and/or communicated to the beam control tray assembly 400 or directly to the main controller 110. Second, the beam control tray assembly 400 optionally communicates the tray type and/or tray insert to the main controller. In various embodiments, communication of the particular tray insert to the main controller 110 is performed: (1) directly from the tray insert, (2) from the tray insert 510 to the tray assembly 400, and/or (3) directly from the tray assembly 400. Generally, communication is performed wirelessly and/or via an established electromechanical link. Identification is optionally performed using a radio-frequency identification label, use of a barcode, or the like, and/or via operator input. Examples are provided to further clarify identification of the patient specific tray insert 510 in a given beam control tray assembly 400 to the main controller.


In a first example, one or more of the patient specific tray inserts 510, such as the range shifter insert 511, the patient specific ridge filter insert 512, the aperture insert 513, the compensator insert 514, or the blank insert 515 include an identifier 520 and/or and a first electromechanical identifier plug 530. The identifier 520 is optionally a label, a radio-frequency identification tag, a barcode, a 2-dimensional bar-code, a matrix-code, or the like. The first electromechanical identifier plug 530 optionally includes memory programmed with the particular patient specific tray insert information and a connector used to communicate the information to the beam control tray assembly 400 and/or to the main controller 110. As illustrated in FIG. 5, the first electromechanical identifier plug 530 affixed to the patient specific tray insert 510 plugs into a second electromechanical identifier plug, such as the tray connector/communicator 430, of the beam control tray assembly 400, which is described infra.


In a second example, the beam control tray assembly 400 uses the second electromechanical identifier plug to send occupancy, position, and/or identification information related to the type or patient specific tray insert 510 associated with the beam control tray assembly to the main controller 110. For example, a first tray assembly is configured with a first tray insert and a second tray assembly is configured with a second tray insert. The first tray assembly sends information to the main controller 110 that the first tray assembly holds the first tray insert, such as a range shifter, and the second tray assembly sends information to the main controller 110 that the second tray assembly holds the second tray insert, such as an aperture. The second electromechanical identifier plug optionally contains programmable memory for the operator to input the specific tray insert type, a selection switch for the operator to select the tray insert type, and/or an electromechanical connection to the main controller. The second electromechanical identifier plug associated with the beam control tray assembly 400 is optionally used without use of the first electromechanical identifier plug 530 associated with the tray insert 510.


In a third example, one type of tray connector/communicator 430 is used for each type of patient specific tray insert 510. For example, a first connector/communicator type is used for holding a range shifter insert 511, while a second, third, fourth, and fifth connector/communicator type is used for trays respectively holding a patient specific ridge filter insert 512, an aperture insert 513, a compensator insert 514, or a blank insert 515. In one case, the tray communicates tray type with the main controller. In a second case, the tray communicates patient specific tray insert information with the main controller, such as an aperture identifier custom built for the individual patient being treated.


Tray Insertion/Coupling


Referring now to FIG. 6A and FIG. 6B a beam control insertion process 600 is described. The beam control insertion process 600 comprises: (1) insertion of the beam control tray assembly 400 and the associated patient specific tray insert 510 into the charged particle beam path 268 and/or gantry nozzle 610, such as into a tray assembly receiver 620 and (2) an optional partial or total retraction of beam of the tray assembly receiver 620 into the gantry nozzle 610.


Referring now to FIG. 6A, insertion of one or more of the beam control tray assemblies 400 and the associated patient specific tray inserts 510 into the gantry nozzle 610 is further described. In FIG. 6A, three beam control tray assemblies, of a possible n tray assemblies, are illustrated, a first tray assembly 402, a second tray assembly 404, and a third tray assembly 406, where n is a positive integer of 1, 2, 3, 4, 5 or more. As illustrated, the first tray assembly 402 slides into a first receiving slot 403, the second tray assembly 404 slides into a second receiving slot 405, and the third tray assembly 406 slides into a third receiving slot 407. Generally, any tray optionally inserts into any slot or tray types are limited to particular slots through use of a mechanical, physical, positional, and/or steric constraints, such as a first tray type configured for a first insert type having a first size and a second tray type configured for a second insert type having a second distinct size at least ten percent different from the first size.


Still referring to FIG. 6A, identification of individual tray inserts inserted into individual receiving slots is further described. As illustrated, sliding the first tray assembly 402 into the first receiving slot 403 connects the associated electromechanical connector/communicator 430 of the first tray assembly 402 to a first receptor 626. The electromechanical connector/communicator 430 of the first tray assembly communicates tray insert information of the first beam control tray assembly to the main controller via the first receptor 626. Similarly, sliding the second tray assembly 404 into the second receiving slot 405 connects the associated electromechanical connector/communicator 430 of the second tray assembly 404 into a second receptor 627, which links communication of the associated electromechanical connector/communicator 430 with the main controller 110 via the second receptor 627, while a third receptor 628 connects to the electromechanical connected placed into the third slot 407. The non-wireless/direct connection is preferred due to the high radiation levels within the treatment room and the high shielding of the treatment room, which both hinder wireless communication. The connection of the communicator and the receptor is optionally of any configuration and/or orientation.


Tray Receiver Assembly Retraction


Referring again to FIG. 6A and FIG. 6B, retraction of the tray receiver assembly 620 relative to a nozzle end 612 of the gantry nozzle 610 is described. The tray receiver assembly 620 comprises a framework to hold one or more of the beam control tray assemblies 400 in one or more slots, such as through use of a first tray receiver assembly side 622 through which the beam control tray assemblies 400 are inserted and/or through use of a second tray receiver assembly side 624 used as a backstop, as illustrated holding the plugin receptors configured to receive associated tray connector/communicators 430, such as the first, second, and third receptors 626, 627, 628. Optionally, the tray receiver assembly 620 retracts partially or completely into the gantry nozzle 146 using a retraction mechanism 660 configured to alternatingly retract and extend the tray receiver assembly 620 relative to a nozzle end 612 of the gantry nozzle, such as a long a first retraction track 662 and a second retraction track 664 using one or more motors and computer control. Optionally the tray receiver assembly 620 is partially or fully retracted when moving the gantry, nozzle, and/or gantry nozzle 610 to avoid physical constraints of movement, such as potential collision with another object in the patient treatment room.


For clarity of presentation and without loss of generality, several examples of loading patient specific tray inserts into tray assemblies with subsequent insertion into an positively charged particle beam path proximate a gantry nozzle are provided.


In a first example, a single beam control tray assembly 400 is used to control the charged particle beam 268 in the charged particle cancer therapy system 100. In this example, a patient specific range shifter insert 511, which is custom fabricated from a patient, is loaded into a patient specific tray insert 510 to form a first tray assembly 402, where the first tray assembly 402 is loaded into the third receptor 628, which is fully retracted into the gantry nozzle 610.


In a second example, two beam control assemblies 400 are used to control the charged particle beam 268 in the charged particle cancer therapy system 100. In this example, a patient specific ridge filter 512 is loaded into a first tray assembly 402, which is loaded into the second receptor 627 and a patient specific aperture 513 is loaded into a second tray assembly 404, which is loaded into the first receptor 626 and the two associated tray connector/communicators 430 using the first receptor 626 and second receptor 627 communicate to the main controller 110 the patient specific tray inserts 510. The tray receiver assembly 620 is subsequently retracted one slot so that the patient specific ridge filter 512 and the patient specific aperture reside outside of and at the nozzle end 612 of the gantry nozzle 610.


In a third example, three beam control tray assemblies 400 are used, such as a range shifter 511 in a first tray inserted into the first receiving slot 403, a compensator in a second tray inserted into the second receiving slot 405, and an aperture in a third tray inserted into the third receiving slot 407.


Generally, any patient specific tray insert 510 is inserted into a tray frame 410 to form a beam control tray assembly 400 inserted into any slot of the tray receiver assembly 620 and the tray assembly is not retracted or retracted any distance into the gantry nozzle 610.


Herein, any number optionally refers to at least that number or less than that number.


Still yet another embodiment includes any combination and/or permutation of any of the elements described herein.


The particular implementations shown and described are illustrative of the invention and its best mode and are not intended to otherwise limit the scope of the present invention in any way. Indeed, for the sake of brevity, conventional manufacturing, connection, preparation, and other functional aspects of the system may not be described in detail. Furthermore, the connecting lines shown in the various figures are intended to represent exemplary functional relationships and/or physical couplings between the various elements. Many alternative or additional functional relationships or physical connections may be present in a practical system.


In the foregoing description, the invention has been described with reference to specific exemplary embodiments; however, it will be appreciated that various modifications and changes may be made without departing from the scope of the present invention as set forth herein. The description and figures are to be regarded in an illustrative manner, rather than a restrictive one and all such modifications are intended to be included within the scope of the present invention. Accordingly, the scope of the invention should be determined by the generic embodiments described herein and their legal equivalents rather than by merely the specific examples described above. For example, the steps recited in any method or process embodiment may be executed in any order and are not limited to the explicit order presented in the specific examples. Additionally, the components and/or elements recited in any apparatus embodiment may be assembled or otherwise operationally configured in a variety of permutations to produce substantially the same result as the present invention and are accordingly not limited to the specific configuration recited in the specific examples.


Benefits, other advantages and solutions to problems have been described above with regard to particular embodiments; however, any benefit, advantage, solution to problems or any element that may cause any particular benefit, advantage or solution to occur or to become more pronounced are not to be construed as critical, required or essential features or components.


As used herein, the terms “comprises”, “comprising”, or any variation thereof, are intended to reference a non-exclusive inclusion, such that a process, method, article, composition or apparatus that comprises a list of elements does not include only those elements recited, but may also include other elements not expressly listed or inherent to such process, method, article, composition or apparatus. Other combinations and/or modifications of the above-described structures, arrangements, applications, proportions, elements, materials or components used in the practice of the present invention, in addition to those not specifically recited, may be varied or otherwise particularly adapted to specific environments, manufacturing specifications, design parameters or other operating requirements without departing from the general principles of the same.


Although the invention has been described herein with reference to certain preferred embodiments, one skilled in the art will readily appreciate that other applications may be substituted for those set forth herein without departing from the spirit and scope of the present invention. Accordingly, the invention should only be limited by the Claims included below.

Claims
  • 1. A method for adjusting a charged particle beam traversing along a charged particle beam path, comprising the steps of: providing a charged particle system, comprising: an accelerator;a beamline from said accelerator to an output nozzle; anda tray assembly;inserting a first tray into a first slot of said tray assembly, said first tray configured with a first insert comprising a patient specific charged particle beam adjustment material, said step of inserting further comprising the steps of: inserting a second tray into a second slot of said tray assembly; andinserting a third tray into a third slot of said tray assembly;after said step of inserting, longitudinally retracting said tray assembly along the charged particle beam path into a zone circumferentially defined by said output nozzle, said step of retracting further comprising the step of: prior to operation of said charged particle system, moving said first slot, said second slot, and said third slot of said tray assembly into the zone circumferentially defined by said output nozzle;attaching a second insert to said second tray prior to said step of retracting; andattaching a third insert to said third tray prior to said step of retracting, wherein each of said first insert, said second insert, and said third insert comprise any of: a patient specific range shifter element comprising a standard thickness of a charged particle beam slowing material;a patient specific ridge filter, comprising a charged particle beam focusing element; anda patient specific blocking material comprising an aperture therethrough, said blocking material blocking the charged particle beam outside of the aperture.
  • 2. The method of claim 1, said step of inserting further comprising the steps of: establishing a first electromechanical connection between a first identifier element, affixed to said first tray, and a first receiver, affixed to said tray assembly; andsaid first identifier element communicating at least one property of said first insert to said charged particle system via said first electromechanical connection.
  • 3. The method of claim 2, said step of communicating further comprising the step of: identifying a patient specific insert installed in said first tray using information digitally stored in said first identifier.
  • 4. The method of claim 2, said step of communicating further comprising the step of: identifying a blank insert installed in said first tray using information digitally stored in said first identifier.
  • 5. The method of claim 2, said step of communicating further comprising the step of: identifying all of: occupancy, type of insert, and slot position to a main controller of said charged particle system.
  • 6. The method of claim 1, said step of retracting further comprising the step of: moving said first slot and not said second slot and not said third slot of said tray assembly into a zone circumferentially defined by said output nozzle.
  • 7. The method of claim 1, said step of retracting further comprising the step of: substantially removing steric limitation of said tray assembly between said output nozzle and a patient.
  • 8. The method of claim 2, said step of communicating further comprising the step of: directly communicating with a main controller of said charged particle system without communication through a sub-assembly not directly in communication with said main controller.
  • 9. An apparatus for adjusting a charged particle beam traversing a charged particle beam path, comprising: a charged particle system, comprising: an accelerator;a beamline from said accelerator to an output nozzle; anda tray assembly longitudinally retractable along the charged particle beam path into a zone circumferentially defined by said output nozzle; anda first tray insertable into a first slot of said tray assembly, said first tray configured with a patient specific charged particle beam adjustment insert during use;a second patient specific tray insertable into a second slot of said tray assembly; anda third patient specific tray insertable into a third slot of said tray assembly,wherein said first slot comprises a first height at least ten percent larger than said second slot, wherein a difference in slot height removes errors associated with a first tray intended for said first slot being inserted into said second slot.
  • 10. The apparatus of claim 9, said first slot further comprising: a lateral orientation, relative to the charged particle beam path through said output nozzle, for insertion of said first patient specific tray.
CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/073,471, filed Mar. 17, 2016 which claims the benefit of U.S. provisional patent application No. 62/304,839 filed Mar. 7, 2016 all of which are incorporated herein in their entirety by this reference thereto.

US Referenced Citations (387)
Number Name Date Kind
2306875 Fremlin Dec 1942 A
2533688 Quam Dec 1950 A
2613726 Paatero Oct 1952 A
2790902 Wright Apr 1957 A
3128405 Lambertson Apr 1964 A
3412337 Lothrop Nov 1968 A
3582650 Avery Jun 1971 A
3585386 Horton Jun 1971 A
3655968 Moore Apr 1972 A
3867705 Hudson Feb 1975 A
3882339 Rate May 1975 A
3906280 Andelfinger Sep 1975 A
3911280 Hyman et al. Oct 1975 A
4002912 Johnson Jan 1977 A
4344011 Hayashi Aug 1982 A
4472822 Swift Sep 1984 A
4607380 Oliver Aug 1986 A
4622687 Whitaker Nov 1986 A
4705955 Mileikowsky Nov 1987 A
4726046 Nunan Feb 1988 A
4730353 Ono Mar 1988 A
4740758 Ries Apr 1988 A
4843333 Marsing et al. Jun 1989 A
4868844 Nunan Sep 1989 A
4870287 Cole Sep 1989 A
4908580 Yamada et al. Mar 1990 A
4989225 Gupta et al. Jan 1991 A
4992746 Martin Feb 1991 A
4996496 Kitamura et al. Feb 1991 A
4998258 Ikeda Mar 1991 A
5010562 Hernandez et al. Apr 1991 A
5017789 Young May 1991 A
5017882 Finlan May 1991 A
5039867 Nishihara Aug 1991 A
5046078 Hernandez et al. Sep 1991 A
5073913 Martin Dec 1991 A
5098158 Palarski Mar 1992 A
5101169 Gomei Mar 1992 A
5117194 Nakanishi May 1992 A
5168241 Hirota Dec 1992 A
5168514 Horton Dec 1992 A
5177448 Ikeguchi Jan 1993 A
5216377 Nakata Jun 1993 A
5260581 Lesyna Nov 1993 A
5285166 Hiramoto Feb 1994 A
5349198 Takanaka Sep 1994 A
5363008 Hiramoto Nov 1994 A
5388580 Sullivan Feb 1995 A
5402462 Nobuta Mar 1995 A
5423328 Gavish Jun 1995 A
5440133 Moyers Aug 1995 A
5483129 Yamamoto Jan 1996 A
5511549 Legg Apr 1996 A
5538494 Matsuda Jul 1996 A
5568109 Takayama Oct 1996 A
5576549 Hell Nov 1996 A
5576602 Hiramoto Nov 1996 A
5585642 Britton Dec 1996 A
5595191 Kirk Jan 1997 A
5600213 Hiramoto Feb 1997 A
5626682 Kobari May 1997 A
5633907 Gravelle May 1997 A
5642302 Dumont Jun 1997 A
5659223 Goodman Aug 1997 A
5661366 Hirota Aug 1997 A
5668371 Deasy Sep 1997 A
5698954 Hirota Dec 1997 A
5760395 Johnstone Jun 1998 A
5789875 Hiramoto Aug 1998 A
5790997 Ruehl Aug 1998 A
5818058 Nakanishi Oct 1998 A
5820320 Kobari Oct 1998 A
5825845 Blair Oct 1998 A
5825847 Ruth Oct 1998 A
5854531 Young et al. Dec 1998 A
5866912 Slater Feb 1999 A
5895926 Britton Apr 1999 A
5907595 Sommerer May 1999 A
5917293 Saito Jun 1999 A
5949080 Ueda et al. Sep 1999 A
5969367 Hiramoto Oct 1999 A
5986274 Akiyama Nov 1999 A
5993373 Nonaka Nov 1999 A
6008499 Hiramoto Dec 1999 A
6034377 Pu Mar 2000 A
6057655 Jongen May 2000 A
6087670 Hiramoto Jul 2000 A
6087672 Matsuda Jul 2000 A
6148058 Dobbs Nov 2000 A
6201851 Piestrup et al. Mar 2001 B1
6207952 Kan Mar 2001 B1
6218675 Akiyama Apr 2001 B1
6236043 Tadokoro May 2001 B1
6265837 Akiyama Jul 2001 B1
6282263 Arndt Aug 2001 B1
6298260 Sontag Oct 2001 B1
6316776 Hiramoto Nov 2001 B1
6322249 Wofford Nov 2001 B1
6335535 Miyake Jan 2002 B1
6339635 Schardt Jan 2002 B1
6356617 Besch Mar 2002 B1
6365894 Tadokoro Apr 2002 B2
6421416 Sliski Jul 2002 B1
6433336 Jongen Aug 2002 B1
6433349 Akiyama Aug 2002 B2
6433494 Kulish Aug 2002 B1
6437513 Stelzer Aug 2002 B1
6444990 Morgan Sep 2002 B1
6462490 Matsuda Oct 2002 B1
6470068 Cheng Oct 2002 B2
6472834 Hiramoto Oct 2002 B2
6476403 Dolinskii Nov 2002 B1
6545436 Gary Apr 2003 B1
6560354 Maurer, Jr. May 2003 B1
6580084 Hiramoto Jun 2003 B1
6597005 Badura Jul 2003 B1
6600164 Badura Jul 2003 B1
6614038 Brand Sep 2003 B1
6617598 Matsuda Sep 2003 B1
6626842 Oka Sep 2003 B2
6635882 Pavlovic Oct 2003 B1
6639234 Badura Oct 2003 B1
6670618 Hartmann Dec 2003 B1
6683318 Haberer Jan 2004 B1
6683426 Kleeven Jan 2004 B1
6710362 Kraft Mar 2004 B2
6717162 Jongen Apr 2004 B1
6725078 Bucholz Apr 2004 B2
6730921 Kraft May 2004 B2
6736831 Hartmann May 2004 B1
6745072 Badura Jun 2004 B1
6774383 Norimine Aug 2004 B2
6777700 Yanagisawa Aug 2004 B2
6785359 Lemaitre Aug 2004 B2
6787771 Bashkirov Sep 2004 B2
6792078 Kato Sep 2004 B2
6799068 Hartmann Sep 2004 B1
6800866 Amemiya Oct 2004 B2
6803591 Muramatsu Oct 2004 B2
6809325 Dahl Oct 2004 B2
6819743 Kato Nov 2004 B2
6822244 Beloussov Nov 2004 B2
6823045 Kato Nov 2004 B2
6838676 Jackson Jan 2005 B1
6842502 Jaffray Jan 2005 B2
6859741 Haberer Feb 2005 B2
6862469 Bucholz Mar 2005 B2
6873123 Marchand Mar 2005 B2
6881970 Akiyama Apr 2005 B2
6891177 Kraft May 2005 B1
6897451 Kaercher May 2005 B2
6900446 Akiyama May 2005 B2
6903351 Akiyama Jun 2005 B1
6903356 Muramatsu Jun 2005 B2
6931100 Kato Aug 2005 B2
6936832 Norimine Aug 2005 B2
6937696 Mostafavi Aug 2005 B1
6953943 Yanagisawa Oct 2005 B2
6979832 Yanagisawa Dec 2005 B2
6984835 Harada Jan 2006 B2
6992312 Yanagisawa Jan 2006 B2
6998258 Kesseler Feb 2006 B1
7012267 Moriyama Mar 2006 B2
7026636 Yanagisawa Apr 2006 B2
7030396 Muramatsu Apr 2006 B2
7045781 Adamec May 2006 B2
7049613 Yanagisawa May 2006 B2
7053389 Yanagisawa May 2006 B2
7054801 Sakamoto May 2006 B2
7058158 Sako Jun 2006 B2
7060997 Norimine Jun 2006 B2
7071479 Yanagisawa Jul 2006 B2
7081619 Bashkirov Jul 2006 B2
7084410 Beloussov Aug 2006 B2
7091478 Haberer Aug 2006 B2
7102144 Matsuda Sep 2006 B2
7109505 Sliski Sep 2006 B1
7122811 Matsuda Oct 2006 B2
7141810 Kakiuchi Nov 2006 B2
7154107 Yanagisawa Dec 2006 B2
7154108 Tadokoro Dec 2006 B2
7173264 Moriyama Feb 2007 B2
7173265 Miller Feb 2007 B2
7193227 Hiramoto Mar 2007 B2
7199382 Rigney Apr 2007 B2
7208748 Sliski Apr 2007 B2
7212608 Nagamine May 2007 B2
7212609 Nagamine May 2007 B2
7227161 Matsuda Jun 2007 B2
7247869 Tadokoro Jul 2007 B2
7252745 Gorokhovsky Aug 2007 B2
7259529 Tanaka Aug 2007 B2
7262424 Moriyama Aug 2007 B2
7274018 Adamec Sep 2007 B2
7274025 Berdermann Sep 2007 B2
7280633 Cheng Oct 2007 B2
7297967 Yanagisawa Nov 2007 B2
7301162 Matsuda Nov 2007 B2
7307264 Brusasco Dec 2007 B2
7310404 Tashiro Dec 2007 B2
7315606 Tsujii Jan 2008 B2
7319231 Moriyama Jan 2008 B2
7342516 Kato et al. Mar 2008 B2
7345291 Kats Mar 2008 B2
7345292 Moriyama Mar 2008 B2
7349522 Yan et al. Mar 2008 B2
7351988 Naumann Apr 2008 B2
7355189 Yanagisawa Apr 2008 B2
7356112 Brown Apr 2008 B2
7368740 Beloussov May 2008 B2
7372053 Yamashita May 2008 B2
7378672 Harada May 2008 B2
7381979 Yamashita Jun 2008 B2
7385203 Nakayama Jun 2008 B2
7394082 Fujimaki Jul 2008 B2
7397054 Natori Jul 2008 B2
7397901 Johnsen Jul 2008 B1
7402822 Guertin Jul 2008 B2
7402823 Guertin Jul 2008 B2
7402824 Guertin Jul 2008 B2
7402963 Sliski Jul 2008 B2
7425717 Matsuda Sep 2008 B2
7432516 Peggs Oct 2008 B2
7439528 Nishiuchi Oct 2008 B2
7446490 Jongen Nov 2008 B2
7449701 Fujimaki Nov 2008 B2
7453076 Welch et al. Nov 2008 B2
7456415 Yanagisawa Nov 2008 B2
7456591 Jongen Nov 2008 B2
7465944 Ueno Dec 2008 B2
7471765 Jaffray Dec 2008 B2
7476883 Nutt Jan 2009 B2
7492858 Partain Feb 2009 B2
7531818 Brahme May 2009 B2
7555103 Johnsen Jun 2009 B2
7560717 Matsuda Jul 2009 B2
7576342 Hiramoto Aug 2009 B2
7586112 Chiba Sep 2009 B2
7589334 Hiramoto Sep 2009 B2
7626347 Sliski Dec 2009 B2
7634057 Ein-Gal Dec 2009 B2
7659521 Pedroni Feb 2010 B2
7668585 Green Feb 2010 B2
7692168 Moriyama Apr 2010 B2
7701677 Schultz Apr 2010 B2
7709818 Matsuda May 2010 B2
7718982 Sliski May 2010 B2
7728311 Gall Jun 2010 B2
7729469 Kobayashi Jun 2010 B2
7741623 Sommer Jun 2010 B2
7755305 Umezawa Jul 2010 B2
7772577 Saito Aug 2010 B2
7796730 Marash Sep 2010 B2
7801277 Zou Sep 2010 B2
7807982 Nishiuchi Oct 2010 B2
7817774 Partain Oct 2010 B2
7817778 Nord Oct 2010 B2
7825388 Nihongi Nov 2010 B2
7826592 Jaffray Nov 2010 B2
7826593 Svensson Nov 2010 B2
7834336 Boeh Nov 2010 B2
7838855 Fujii Nov 2010 B2
7848488 Mansfield Dec 2010 B2
7860216 Jongen Dec 2010 B2
7875868 Moriyama Jan 2011 B2
7894574 Nord Feb 2011 B1
7906769 Blasche Mar 2011 B2
7919765 Timmer Apr 2011 B2
7939809 Balakin May 2011 B2
7940891 Star-Lack May 2011 B2
7940894 Balakin May 2011 B2
7943913 Balakin May 2011 B2
7953205 Balakin May 2011 B2
7961844 Takeda Jun 2011 B2
7977656 Fujimaki Jul 2011 B2
7982198 Nishiuchi Jul 2011 B2
7987053 Schaffner Jul 2011 B2
7995813 Foshee Aug 2011 B2
8002465 Ahn Aug 2011 B2
8003964 Stark Aug 2011 B2
8009804 Siljamaki Aug 2011 B2
8045679 Balakin Oct 2011 B2
8067748 Balakin Nov 2011 B2
8089054 Balakin Jan 2012 B2
8093564 Balakin Jan 2012 B2
8139712 Kojima Mar 2012 B2
8309941 Balakin Nov 2012 B2
8374314 Balakin Feb 2013 B2
20010009267 Tadokoro Jul 2001 A1
20030031297 Mateo Feb 2003 A1
20030141460 Kraft Jul 2003 A1
20030163015 Yanagisawa Aug 2003 A1
20030164459 Schardt Sep 2003 A1
20040022361 Lemaitre Feb 2004 A1
20040062354 Kato Apr 2004 A1
20040155206 Marchand Aug 2004 A1
20040184583 Nagamine et al. Sep 2004 A1
20040218725 Radley Nov 2004 A1
20040227074 Benveniste et al. Nov 2004 A1
20040254492 Zhang Dec 2004 A1
20050017193 Jackson Jan 2005 A1
20050051740 Yanagisawa Mar 2005 A1
20050099145 Nishiuchi et al. May 2005 A1
20050148808 Cameron Jul 2005 A1
20050161618 Pedroni Jul 2005 A1
20050167610 Tajima Aug 2005 A1
20050211905 Stark Sep 2005 A1
20050238134 Brusasco Oct 2005 A1
20050269497 Jongen Dec 2005 A1
20050284233 Teraura et al. Dec 2005 A1
20060015202 Sweat Jan 2006 A1
20060050848 Vilsmeier Mar 2006 A1
20060106301 Kats May 2006 A1
20060163495 Hiramoto Jul 2006 A1
20060171508 Noda Aug 2006 A1
20060180158 McKnight et al. Aug 2006 A1
20060226372 Yanagisawa Oct 2006 A1
20060255285 Jongen Nov 2006 A1
20060262898 Partain Nov 2006 A1
20070018121 Leyman Jan 2007 A1
20070027389 Wesse Feb 2007 A1
20070040115 Publicover Feb 2007 A1
20070051905 Fujimaki et al. Mar 2007 A1
20070093723 Keall Apr 2007 A1
20070121788 Mildner May 2007 A1
20070170994 Peggs Jul 2007 A1
20070181815 Ebstein Aug 2007 A1
20070189461 Sommer Aug 2007 A1
20070211854 Koshnitsky et al. Sep 2007 A1
20070215819 Hiramoto Sep 2007 A1
20070228291 Hiramoto Oct 2007 A1
20070228304 Nishiuchi Oct 2007 A1
20070269000 Partain et al. Nov 2007 A1
20080023644 Pedroni Jan 2008 A1
20080067405 Nihongi et al. Mar 2008 A1
20080093567 Gall Apr 2008 A1
20080139955 Hansmann Jun 2008 A1
20080191142 Pedroni Aug 2008 A1
20080267352 Aoi Oct 2008 A1
20080290297 Blasche et al. Nov 2008 A1
20080317202 Partain et al. Dec 2008 A1
20090096179 Stark Apr 2009 A1
20090140672 Gall Jun 2009 A1
20090168960 Jongen Jul 2009 A1
20090184263 Moriyama Jul 2009 A1
20090189095 Flynn Jul 2009 A1
20090200483 Gall Aug 2009 A1
20090236545 Timmer Sep 2009 A1
20090261248 Glavish et al. Oct 2009 A1
20090283704 Nishiuchi Nov 2009 A1
20090289194 Saito Nov 2009 A1
20090304153 Amelia Dec 2009 A1
20090314960 Balakin Dec 2009 A1
20090314961 Balakin Dec 2009 A1
20100001212 Nishiuchi Jan 2010 A1
20100006106 Balakin Jan 2010 A1
20100008468 Balakin Jan 2010 A1
20100008469 Balakin Jan 2010 A1
20100027745 Balakin Feb 2010 A1
20100033115 Cleland Feb 2010 A1
20100045213 Sliski Feb 2010 A1
20100059688 Claereboudt Mar 2010 A1
20100060209 Balakin Mar 2010 A1
20100090122 Balakin Apr 2010 A1
20100091948 Balakin Apr 2010 A1
20100128846 Balakin May 2010 A1
20100230617 Gall Sep 2010 A1
20100272241 Amelia Oct 2010 A1
20100308235 Sliski Dec 2010 A1
20110073778 Natori Mar 2011 A1
20110080172 Banning-Geertsma Apr 2011 A1
20110089329 Jongen Apr 2011 A1
20110127443 Comer Jun 2011 A1
20110137159 Jongen Jun 2011 A1
20110147608 Balakin Jun 2011 A1
20110174984 Balakin Jul 2011 A1
20110178359 Hirschman et al. Jul 2011 A1
20110186720 Jongen Aug 2011 A1
20110233423 Balakin Sep 2011 A1
20110278477 Balakin Nov 2011 A1
20110284760 Balakin Nov 2011 A1
20110284762 Balakin Nov 2011 A1
20110313232 Balakin Dec 2011 A1
20120043472 Balakin Feb 2012 A1
20120205551 Balakin Aug 2012 A1
20120209109 Balakin Aug 2012 A1
20160045769 Amelia Feb 2016 A1
Foreign Referenced Citations (8)
Number Date Country
1683545 Jul 2006 EP
1270619 Apr 1972 GB
WO 9953998 Oct 1999 WO
WO 014026 Jan 2007 WO
WO 2008044194 Apr 2008 WO
WO2010101489 Mar 2009 WO
WO 2009142546 Nov 2009 WO
WO 2009142550 Nov 2009 WO
Non-Patent Literature Citations (28)
Entry
Adams, “Electrostatic cylinder lenses II: Three Element Einzel Lenses”, Journal, Feb. 1, 1972, pp. 150-155, XP002554355, vol. 5 No. 2, Journal of Physics E.
Amaldi, “A Hospital-Based Hadrontherapy Complex”, Journal, Jun. 27, 1994, pp. 49-51, XP002552288, Proceedings of Epac 94, London, England.
Arimoto, “A Study of the PRISM-FFAG Magnet”, Journal, Oct. 18, 2004,Oct. 22, 2004, pp. 243-245, XP002551810, Proceedings of Cyclotron 2004 Conference, Tokyo, Japan.
Biophysics Group et al. “Design, Construction and First Experiment of a Magnetic Scanning System for Therapy, Radiobiological Experiment on the Radiobiological Action of Carbon, Oxygen and Neon” GSI Report, Gessellschaft fur Schwerionenforschung MBH. vol. GSI-91-18, Jun. 1, 1991, pp. 1-31.
Blackmore, “Operation of the TRIUMF Proton Therapy Facility”, Book, May 12, 1997, pp. 3831-3833, XP010322373, vol. 3, Proceedings of the 1997 Particle Accelerator Conference, NJ, USA.
Bryant, “Proton-Ion Medical Machine Study (PIMMS) Part II”, Book, Jul. 27, 2000, p. 23,p. 228,pp. 289-290, XP002551811, European Organisation for Nuclear Research Cern-Ps Division, Geneva, Switzerland.
Craddock, “New Concepts in FFAG Design for Secondary Beam Facilities and other Applications”, Journal, May 16, 2005,May 20, 2005, pp. 261-265, XP002551806, Proceedings of 2005 Particle Accelerator Conference, Knoxville, Tennessee, USA.
Dzhelepov, “Use of USSR Proton Accelerators for Medical Purposes”, Journal,Jun. 1973, pp. 268-270, vol. ns-2—No. 3, XP002553045, IEEE Transactions on Nuclear Science USA, USA.
Endo, “Medical Synchrotron for Proton Therapy” Journal, Jun. 7, 1988,Jun. 11, 1988, pp. 1459-1461, XP002551808, Proceedings of Epac 88, Rome, Italy.
European Organization for Nuclear Research Cern, Jul. 27, 2000, pp. 1-352.
Johnstone, Koscielniak, “Tune-Stabilized Linear-Field FFAG for Carbon Therapy”, Journal, Jun. 26, 2006,Jun. 30, 2006, XP002551807, Proceedings of EPAC 2006, Edinburgh, Scotland, UK.
Kalnins, “The use of electric multiple lenses for bending and focusing polar molecules, with application to the design of a rotational-state separator”, Journal, May 17, 2003,May 21, 2003, pp. 2951-2953, XP002554356, Proceeding of Pac 2003, Portland, Oregon, USA.
Kim, “50 MeV Proton Beam Test Facility for Low Flux Beam Utilization Studies of PEFP”, Journal, Oct. 31, 2005, pp. 441-443, XP002568008, Proceedings of Apac 2004, Pohang, Korea.
Lapostolle, “Introduction a la theorie des accelerateurs lineaires”, Book, Jul. 10, 1987, pp. 4-5, XP002554354, Cern Yellow Book Cern, Geneva, Switzerland.
Li, “A thin Beryllium Injection Window for CESR-C”, Book, May 12, 2003, pp. 2264-2266, XP002568010, vol. 4, PAC03, Portland, Oregon, USA.
Noda, “Slow beam extraction by a transverse RF field with AM and FM”, Journal, May 21, 1996, pp. 269-277, vol. A374, XP002552289, Nuclear Instruments and Methods in Physics Research A, Eslevier, Amsterdam, NL.
Noda, “Performance of a respiration-gated beam control system for patient treatment”, Journal, Jun. 10, 1996, Jun. 14, 1996, pp. 2656-2658, XP002552290, Proceedings Epac 96, Barcelona, Spain.
Peters, “Negative ion sources for high energy accelerators”, Journal, Feb. 1, 2000, pp. 1069-1074, XP012037926, vol. 71—No. 2,Review of Scientific Instruments, Melville, NY, USA.
Pohlit, “Optimization of Cancer Treatment with Accelerator Produced Radiations”, Journal, Jun. 22, 1998, pp. 192-194, XP002552855, Proceedings EPAC 98, Stockholm, Sweden.
Proceeding of 2004 Cyclotron Conference, Oct. 18, 2004, pp. 246-428.
Proceedings of Cyclotron 2004 Conference, Oct. 18, 2004, pp. 243-245 (Presentation Material pp. 1-30).
Proceedings of EPAC 2006, Jun. 30, 2006, pp. 2290-2292.
Proceeding of 2005 Particle Accelerator Conference, May 16, 2005, pp. 261-265.
Saito, “RF Accelerating System for Compact Ion Synchrotron”, Journal, Jun. 18, 2001, pp. 966-968, XP002568009, Proceeding of 2001 Pac, Chicago, USA.
Suda, “Medical Application of the Positron Emitter Beam at HIMAC”, Journal, Jun. 26, 2000, Jun. 30, 2000 pp. 2554-2556, XP002553046, Proceedings of EPAC 2000, Vienna, Austria.
Tanigaki, “Construction of FFAG Accelerators in KURRI for ADS Study”, May 16, 2005,May 20, 2005, pp. 350-352, XP002551809, Proceedings of 2005 Particle Accelerator Conference, Knoxville, Tennessee, USA.
Trbojevic, “Design of a Non-Scaling FFAG Accelerator for Proton Therapy”, Journal, Oct. 18, 2004,Oct. 22, 2004, pp. 246-248, XP002551805, Proceedings of 2004 Cyclotron Conference, Tokyo, Japan.
Winkler, “Charge Exchange Extraction at the Experimental Storage Ring ESR at GSI”, Journal, Jun. 22, 1998, p. 559-561, XP002552287, Proceedings of Epac 98, Stockholm, Sweden.
Related Publications (1)
Number Date Country
20170252580 A1 Sep 2017 US
Provisional Applications (1)
Number Date Country
62304839 Mar 2016 US
Continuations (1)
Number Date Country
Parent 15073471 Mar 2016 US
Child 15382401 US